There are recent preclinical background (Bozec et al, 2006) and early clinical trials (Caponigro et al, 2005; Meyerhardt et al, 2007) that indicate that targeting both EGFR pathway and tumour angiogenesis may be a useful strategy in the management of several tumour pathologies. Here, EGFR is linked to neoplasm.